The controversial Commissioner’s National Priorities Voucher program awards “ultra-fast” reviews for medications and biological products of strategic national importance while upholding the FDA’s standards.
The US Food and Drug Administration (FDA) is seeking public comment on the controversial Commissioner’s National Priority Voucher (CNPV) pilot program.
The CNPV pilot program was established in June 2025 to address “critical public health needs” by providing an “ultra-fast” review pathway for drugs and biological products of strategic national importance
Read more articles like this one with our free plan, or get our Premium plan for access to all content – including our 5,000+ article archive, exclusive interviews, podcasts, and more.
